高级检索
当前位置: 首页 > 详情页

Survival prediction for patients with lung adenocarcinoma: A prognostic risk model based on gene mutations

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Pathology, Tianjin Chest Hospital, Tianjin, China [2]Tianjin Marvel Medical Laboratory, Tianjin Marvelbio Technology Co., Ltd, Tianjin, China [3]Department of Medical Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
出处:
ISSN:

关键词: Lung adenocarcinoma gene mutation signature prognosis a risk model

摘要:
BACKGROUND: Lung adenocarcinoma is the most common type of lung cancer, and it is one of the most aggressive and rapidly fatal tumor types. OBJECTIVE: To identify a signature mutation genes for prognostic prediction of lung adenocarcinoma. METHODS: Four hundred and sixty-two lung adenocarcinoma cases were screened out and downloaded from TCGA database. Mutation data of 18 targeted genes were detected by MuTect. LASSO-COX model was used to screen gene loci, and then a prognosis model was established. Afterwards, 40 clinical patients of lung adenocarcinoma were collected to verify the mutation features and the predictive function of the above prognostic model. The mutations of above 18 genes were sequenced with targeted next generation sequencing (NGS) and analyzed with GATK and MuTect. RESULTS: TP53 (282, 32.38%), NF1 (82, 9.41%) and EGFR (80, 9.18%) were the top 3 most frequent mutation genes. A total of 7 variables were screened out after lasso-COX analysis (tumor stage, age, diagnostic type, SMARCA4, GNAS, PTCH2, TSC2). SMARCA4, GNAS and TSC2 were a gene mutation signature to predict a poor prognosis. CONCLUSIONS: We established a prognostic model for lung adenocarcinoma, and further concluded that SMARCA4, GNAS and TSC2 were a gene signature which plays a prognostic role.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2020]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2020]版:
Q2 ONCOLOGY
最新[2024]版:
Q3 ONCOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Department of Pathology, Tianjin Chest Hospital, Tianjin, China
通讯作者:
通讯机构: [1]Department of Pathology, Tianjin Chest Hospital, Tianjin, China [3]Department of Medical Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China [*1]Department of Pathology, Tianjin Chest Hospital, No. 261 Taierzhuang South Road, Tianjin 300222, China. [*2]Department of Medical Oncology, Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang, Hebei 050011, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号